--- title: "The Stock Connect Innovative Drug ETF E Fund (159316) attracted over RMB 1.8 billion in the past three months." type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/43449095.md" description: "As of 9:57, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) rose 0.07%. Among weighted stocks, Innovent Biologics fell 1.52%, BeiGene rose 1.87%, CSPC Pharmaceutical Group fell 0.63%, Akeso fell 2.15%, China Biologic Products fell 1.04%, Hansoh Pharmaceutical rose 0.49%, Simcere Pharmaceutical fell 1.32%, Kelun-Biotech fell 0.1%, Zai Lab fell 0.15%, and Confo Therapeutics-B fell 2.07%. The E Fund Stock Connect Innovative Drug ETF (159316) continues to see capital inflows. As of the previous trading day..." datetime: "2026-08-18T04:29:24.000Z" locales: - [en](https://longbridge.com/en/topics/43449095.md) - [zh-CN](https://longbridge.com/zh-CN/topics/43449095.md) - [zh-HK](https://longbridge.com/zh-HK/topics/43449095.md) author: "[同壁财经](https://longbridge.com/en/profiles/26505347.md)" --- # The Stock Connect Innovative Drug ETF E Fund (159316) attracted over RMB 1.8 billion in the past three months. As of 9:57, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) rose 0.07%. Among weighted stocks, Innovent Biologics fell 1.52%, BeiGene rose 1.87%, CSPC Pharmaceutical Group fell 0.63%, Akeso fell 2.15%, China Biopharmaceutical Products fell 1.04%, Hansoh Pharmaceutical rose 0.49%, Simcere Pharmaceutical fell 1.32%, Kelun-Biotech fell 0.1%, Zai Lab fell 0.15%, and Clarity Biosciences -B fell 2.07%. The E Fund Stock Connect Innovative Drug ETF (159316) continues to see capital inflows. As of the previous trading day, the fund recorded net inflows of RMB 227mn over the past month, RMB 1.891bn over the past three months, RMB 2.938bn over the past six months, and RMB 6.616bn over the past year. The fund's average daily turnover for the past month was RMB 1.045bn, ranking first among peers, with active on-exchange trading and strong liquidity. In news developments, from August 3 to August 9, 2026, a total of 11 therapeutic new drugs and vaccine products received marketing approval globally, with regulatory bodies including China's NMPA, the US FDA, and the European Medicines Agency. Geographically, 6 drugs were approved domestically, while 5 were approved in the US and Europe. Domestic innovative drugs include both first-in-class breakthroughs and improved new drugs, while overseas approvals feature multiple technologies achieving industry milestone breakthroughs. Guosen Securities noted that long-term trends show clear specialization in global pharmaceutical R&D. To control costs, shorten R&D cycles, and focus on core innovation, pharma companies are increasingly outsourcing drug discovery, preclinical research, clinical trials, and manufacturing, driving steady expansion of the CXO sector. The E Fund Stock Connect Innovative Drug ETF (159316) is currently the only ETF tracking the Hang Seng Innovative Drug Index, offering high elasticity and scarcity to better capture opportunities in this round of Hong Kong innovative drug growth. E Fund Asset Management is a leading comprehensive asset manager in China with over 20 years of expertise in index investment. Its index product line comprehensively covers mainstream broad-based indices, multiple sector indices, cross-border and cross-market indices, reaching over 10 exchanges globally. Its professional index research team possesses extensive experience in product design and investment management. Related products: E Fund Stock Connect Innovative Drug ETF (159316) E Fund Hang Seng Stock Connect Innovative Drug Feeder Fund A (024328) E Fund Hang Seng Stock Connect Innovative Drug Feeder Fund C (024329) E Fund Innovative Drug ETF (516080), Off-exchange feeder (Class A: 019666; Class C: 019667) E Fund Stock Connect Healthcare ETF (513200), Off-exchange feeder (Class A: 018557; Class C: 018558) E Fund Healthcare ETF (512010), Off-exchange feeder (Class A: 001344; Class C: 007883) E Fund Medical ETF (159847), Off-exchange feeder (Class A: 017937; Class C: 017938) E Fund Biotechnology ETF (159837), Off-exchange feeder (Class A: 019324; Class C: 019325) ### Related Stocks - [159776.CN](https://longbridge.com/en/quote/159776.CN.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) - [02162.HK](https://longbridge.com/en/quote/02162.HK.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [09926.HK](https://longbridge.com/en/quote/09926.HK.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [01530.HK](https://longbridge.com/en/quote/01530.HK.md) - [002736.CN](https://longbridge.com/en/quote/002736.CN.md) - [06990.HK](https://longbridge.com/en/quote/06990.HK.md) - [09688.HK](https://longbridge.com/en/quote/09688.HK.md) - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md)